2025-06-15-Jefferies-赛智治疗公司（SAGE）_SAGE_关于Supernus_Pharma收购的思考_12页_1mb

Sage Therapeutics Equity Research Summary

Acquired by Supernus Pharma for $8.50/share with CVRs

• Deal terms: $8.50/share upfront cash plus up to $3.50/share in contingent value rights (CVRs) tied to Zurzuvae sales milestones.
• CVR milestones: US-based net sales thresholds require SUPN to hit $250M by end of 2027, $300M by 2028, and $375M by 2030. Japan MDD approval uncertain.
• Jefferies price target increase: PT raised from $8.00 to $8.50 (27%) due to peak sales projection of $309M for Zurzuvae.

Analyst Recommendations and Key Concerns

• Hold rating: Jefferies believes the deal is reasonable for shareholders but doubts CVR milestones are achievable due to high sales thresholds and regulatory uncertainty.
• Downside risks: Slow sales growth, competitive pressures, and potential delays in regulatory approvals highlighted.
• Positive outlook: Zurzuvae's performance (e.g., $18.7M in Q2) supports continued revenue potential, and the pipeline (e.g., SAGE-324) holds promise for future growth.

Investment Thesis and Long-Term View

• Upside potential: If Zurzuvae achieves broad market penetration, revenue could reach ~$350M peak.
• Key risks: Uncertain MDD approvals in Japan, competition from generic versions, and slower-than-expected commercialization.
• ESG focus: Emphasis on improving patient access through partnerships, with notable investor questions on collaboration strategies.

Summary Insights

• The acquisition is viewed as a reasonable exit strategy, but shareholders should monitor CVR milestone risks and global expansion challenges.
• Financial metrics: Current market cap $414.4M, with projected US revenue growth in the 2020s if milestones are met.